Loading...
•
Jun 30, 2021
Celldex Q2 2021 Earnings Report
Reported financial results for the second quarter ended June 30, 2021 and provided a corporate update.
Key Takeaways
Celldex reported a total revenue of $3.5 million and a net loss of $13.4 million, or ($0.34) per share, for the second quarter of 2021. The company's cash, cash equivalents and marketable securities were $164.0 million as of June 30, 2021. They raised $287 million in gross proceeds from a follow-on public offering of common stock, closed in July 2021.
Reported positive data from CDX-0159 Phase 1b Study in Chronic Inducible Urticaria presented at EAACI 2021
Raised $287 million in gross proceeds from a follow-on public offering of common stock, closed in July 2021
Cash, cash equivalents and marketable securities as of June 30, 2021 were $164.0 million
Total revenue was $3.5 million in the second quarter of 2021
Celldex
Celldex
Forward Guidance
Celldex believes that the cash, cash equivalents and marketable securities at June 30, 2021, along with the approximately $270.0 million in net proceeds raised in our July 2021 underwritten public offering of common stock, are sufficient to meet estimated working capital requirements and fund planned operations through 2025.